20101005
 Corporate News: Novartis Cites Discontinued Drugs for Charge   By Mijuk, Goran, The Wall Street Journal,  Oct 6, 2010  While part of normal product adjustment, the research discontinuation of the two drugs was also seen as another indication of Novartis's efforts to restructure its broad product portfolio that includes blockbusters such as heart drug Diovan and cancer medicine Glivec and a flurry of experimental compounds.   
